Metajodobenzyloguanidyna-123i (Mibg-123i) Narodowe Centrum Badań Jądrowych (Iobenguane Sulfate I-123)

Iobenguane sulfate I-123 mimics norepinephrine and is actively transported into cells that express the norepinephrine transporter (NET). Once inside, the I-123 isotope emits gamma radiation that is captured by SPECT cameras, producing high‑resolution images of NET‑rich tissues.

The administered activity of Metajodobenzyloguanidyna-123i is determined by the prescribing nuclear medicine physician or radiologist based on patient weight, age, the specific diagnostic protocol, and regulatory limits. No fixed dose is provided in public literature.

Safety data for Iobenguane sulfate I-123 in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and use is generally avoided unless the diagnostic benefit is essential. Breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Metajodobenzyloguanidyna-123i, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternative is Iobenguane I-131, which emits beta particles and has a longer half‑life, making it suitable for therapeutic purposes but less optimal for high‑resolution imaging. I-123 provides superior image quality, lower radiation dose to the patient, and faster imaging protocols, making it the preferred choice for diagnostic scans.

Metajodobenzyloguanidyna-123i must be stored refrigerated between 2 °C and 8 °C, protected from light, and kept in its original shielding container. It should not be frozen or shaken, and any unused portion must be disposed of according to local radiopharmaceutical waste regulations.

The product is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The injection is typically performed in a controlled nuclear medicine suite, followed by a waiting period to allow tracer distribution before imaging with a gamma camera or SPECT system.

Serious risks include rare allergic reactions such as anaphylaxis, severe hypotension immediately after injection, and, in extremely uncommon cases, radiation‑induced tissue injury in high‑uptake organs. Patients should be monitored during and after administration, and emergency equipment must be available.

Patients with known severe hypersensitivity to Iobenguane or any component of the formulation should avoid the product. It is also contraindicated in pregnant women unless the diagnostic benefit outweighs the risk, and caution is advised for breastfeeding mothers, individuals on high‑dose sympathomimetic drugs, and those with uncontrolled severe cardiac conditions.